ResearchMoz

Breast Cancer Therapeutics in Major Developed Markets to 2020 - Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted Drugs

GBI Research
Published Date » 2014-06-02
No. Of Pages » N/A
   
 GBI Research, the leading business intelligence provider, has released its latest research: ‘Breast Cancer Therapeutics in Major Developed Markets to 2020 – Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted Drugs ’, which provides in-depth analysis of breast cancer therapeutics market within the eight major geographies of the US, Canada, the top five geographies in Europe (the UK, France, Germany, Spain and Italy) and Japan. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis. The breast cancer therapeutics market in the eight major markets – The US, The...
Table of Content

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8

2 Breast Cancer Therapeutics in Major Developed Markets to 2020 – Introduction 9
2.1 Breast Cancer 9
2.2 Symptoms 9
2.3 Epidemiology 10
2.4 Pathophysiology 11
2.5 Diagnosis 11
2.6 Prognosis and Disease Staging 12
2.6.1 Classification 13
2.7 Treatment Options 14
2.7.1 Surgery and Radiation Therapy 14
2.7.2 Chemotherapy 14
2.7.3 Hormonal Therapies 15
2.7.4 Targeted Therapies 15
2.7.5 Resistance to Pharmacological Therapies 16
2.7.6 Treatment Guidelines 17
2.7.7 Measuring the Effectiveness of Treatment 18

3 Breast Cancer Therapeutics in Major Developed Markets to 2020 – Marketed Products 20
3.1 Key Marketed Products 20
3.1.1 Herceptin 20
3.1.2 Halaven 21
3.1.3 Avastin 22
3.1.4 Gemzar 23
3.1.5 Taxotere 23
3.1.6 Tykerb 24
3.1.7 Femara 25
3.1.8 Aromasin 26
3.1.9 Zoladex 26
3.1.10 Arimidex 27
3.2 Heat Map for Marketed Products 27

4 Breast Cancer Therapeutics in Major Developed Markets to 2020 – Pipeline Analysis 29
4.1 Overall Pipeline 29
4.2 Pipeline Analysis by Molecule Type 31
4.3 Pipeline Analysis by Mechanism of Action 33
4.4 Clinical Trials - Failure Rate 35
4.5 Clinical Trial Size 37
4.6 Duration 39
4.7 Promising Drug Candidates in Pipeline 40
4.7.1 Buparlisib 40
4.7.2 Palbociclib 40
4.7.3 Afatinib dimaleate 40
4.7.4 Entinostat 41
4.7.5 Neratinib 42
4.7.6 BMN-673 42
4.7.7 Etirinotecan pegol 42
4.7.8 MetmAb (onartuzumab) 43

5 Breast Cancer Therapeutics in Major Developed Markets to 2020 – Market Forecast to 2020 44
5.1 Global Market 44
5.1.1 Treatment Use Patterns 44
5.1.2 Market Size 44
5.2 North America 46
5.2.1 Treatment Use Patterns 46
5.2.2 Annual Cost of Therapy 47
5.2.3 Market Size 49
5.3 Top Five European Markets 51
5.3.1 Treatment Use Patterns 51
5.3.2 Annual Cost of Therapy 52
5.3.3 Market Size 53
5.4 Japan 54
5.4.1 Treatment Use Patterns 54
5.4.2 Annual Cost of Therapy 54
5.4.3 Market Size 54
5.5 Drivers and Barriers for the Breast Cancer Therapeutics in Asia-Pacific Market to 2020 56
5.5.1 Drivers 56
5.5.2 Barriers 56

6 Breast Cancer Therapeutics in Major Developed Markets to 2020 – Deals and Strategic Consolidations 58
6.1 Licensing Agreements 58
6.1.1 Major Licensing Deals 61
6.2 Co-development Agreements 62
6.2.1 Major Co-development Agreements 64

7 Breast Cancer Therapeutics in Major Developed Markets to 2020 – Appendix 66
7.1 All Pipeline Drugs by Phase 66
7.1.1 Discovery 66
7.1.2 Preclinical 69
7.1.3 IND/CTA-Filed and Phase I 79
7.1.4 Phase II 85
7.1.5 Phase III 91
7.1.6 Pre-Registration 93
7.2 Market Forecasts to 2020 94
7.2.1 Global 94
7.2.2 US 94
7.2.3 Canada 95
7.2.4 UK 95
7.2.5 France 95
7.2.6 Germany 96
7.2.7 Italy 96
7.2.8 Spain 96
7.2.9 Japan 97
7.3 Market Definitions 97
7.4 Abbreviations 97
7.5 References 99
7.6 Research Methodology 102
7.6.1 Coverage 102
7.6.2 Secondary Research 102
7.6.3 Primary Research 103
7.6.4 Therapeutic Landscape 103
7.6.5 Geographical Landscape 105
7.6.6 Pipeline Analysis 106
7.7 Expert Panel Validation 106
7.8 Contact Us 106
7.9 Disclaimer 106

List of Tables

Table 1: Breast Cancer Therapeutics, Global, Tumor, Nodes and Metastasis Staging, 2010–2013 12
Table 2: Breast Cancer Therapeutics, US, Disease Stage at Diagnosis and Five-Year Relative Survival (%), 2013 13
Table 3: Breast Cancer Therapeutics, Global, All Pipeline Products (Discovery), 2013 66
Table 4: Breast Cancer Therapeutics, Global, All Pipeline Products (Preclinical), 2013 69
Table 5: Breast Cancer Therapeutics, Global, All Pipeline Products (IND/CTA-Filed and Phase I), 2013 79
Table 6: Breast Cancer Therapeutics, Global, All Pipeline Products (Phase II), 2013 85
Table 7: Breast Cancer Therapeutics, Global, All Pipeline Products (Phase III), 2013 91
Table 8: Breast Cancer Therapeutics, Global, All Pipeline Products (Pre-Registration), 2013 93
Table 9: Breast Cancer Therapeutics, Global, Forecast Data, 2013–2020 94
Table 10: Breast Cancer Therapeutics, US, Forecast Data, 2013–2020 94
Table 11: Breast Cancer Therapeutics, Canada, Forecast Data, 2013–2020 95
Table 12: Breast Cancer Therapeutics, UK, Forecast Data, 2013–2020 95
Table 13: Breast Cancer Therapeutics, France, Forecast Data, 2013–2020 95
Table 14: Breast Cancer Therapeutics, Germany, Forecast Data, 2013–2020 96
Table 15: Breast Cancer Therapeutics, Italy, Forecast Data, 2013–2020 96
Table 16: Breast Cancer Therapeutics, Spain, Forecast Data, 2013–2020 96
Table 17: Breast Cancer Therapeutics, Japan, Forecast Data, 2013–2020 97

List of Figures

Figure 1: Breast Cancer Therapeutics, Global, Treatment Algorithm for Cancer Diagnosed at Stages I to III, 2013 17
Figure 2: Breast Cancer Therapeutics, Global, Treatment Algorithm for Cancer Diagnosed at Stage IV, 2013 18
Figure 3: Breast Cancer Therapeutics, Global, Heat Map (Marketed Products) 28
Figure 4: Breast Cancer Therapeutics, Global, Pipeline by Stage of Development and Program Type, 2013 30
Figure 5: Breast Cancer Therapeutics, Global, Pipeline by Molecule Type and Stage of Development, 2013 32
Figure 6: Breast Cancer Therapeutics, Global, Pipeline by Mechanism of Action and Stage of Development, 2013 34
Figure 7: Breast Cancer Therapeutics, Global, Clinical Trial Failure Rate (%), 2013 36
Figure 8: Breast Cancer Therapeutics, Global, Clinical Trial Size, 2013 38
Figure 9: Breast Cancer Therapeutics, Global, Clinical Trial Duration (months), 2013 39
Figure 10: Breast Cancer Therapeutics, Global, Treatment Use Patterns (‘000) and Market Size ($bn), 2013–2020 45
Figure 11: Breast Cancer Therapeutics, US and Canada, Treatment Use Patterns (‘000), 2013–2020 46
Figure 12: Breast Cancer Therapeutics, US and Canada, Annual Cost of Therapy ($), 2013–2020 48
Figure 13: Breast Cancer Therapeutics, US and Canada, Market Size ($m), 2013–2020 50
Figure 14: Breast Cancer Therapeutics, Top Five European Markets, Treatment Use Patterns (‘000), 2013–2020 51
Figure 15: Breast Cancer Therapeutics, Top Five European Markets, Annual Cost of Therapy ($), 2013–2020 52
Figure 16: Breast Cancer Therapeutics, Top Five European Markets, Market Size ($m), 2013–2020 53
Figure 17: Breast Cancer Therapeutics, Japan, Treatment Use Pattern, Annual Cost of Therapy and Market Size, 2013–2020 55
Figure 18: Breast Cancer Therapeutics, Global, Licensing Deals by Phase and Value, 2006–2013 58
Figure 19: Breast Cancer Therapeutics, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006–2013 59
Figure 20: Breast Cancer Therapeutics, Global, Licensing Deals by Region, 2006–2013 60
Figure 21: Breast Cancer Therapeutics, Global, Co-development Deals by Phase and Value, 2006–2013 62
Figure 22: Breast Cancer Therapeutics, Global, Co-development Deals, 2006–2013 63
Figure 23: GBI Research Market Forecasting Model 105

Upcoming Reports:

Metallocene Technologies Market- Global Industry Analysis, Market Share, Size, Growth, Trends, and Forecast, 2012 - 2018
By - Transparency Market Research
Metallocene based technology is estimated to boost the growth of the polyolefin polyethylene, and polypropylene industries. The major players operating in the global polyethylene and polypropylene industries invest heavily in developing metallocene technologies to obtain a cutting edge advantage over their competitors.  The investment made for developing metallocene technologies accounts for approximately 75% of the total R&D investment made in the polyolefins industry with the remaining being spent for nourishing conventional technologies. Metallocene based...
Dolomite Mining Market - Global Industry Analysis, Market Size, Share, Growth, Trends And Forecast 2014 - 2020
By - Transparency Market Research
With the rapid increase in the construction and mining activities for dolomite, the market for dolomite mining and equipments has the potential to exhibit significant growth in the future. According to Mineral planning factsheet, out of a total of 12.2 Million tons of Dolomite mined in the United Kingdom, around 10.8 Million tons is used in the construction industry. Nearly 50 % of world’s carbonate reserves are in dolomite and these dolomite reserves can also host a significant amount of hydrocarbons. Hence with an abundance of reserves, diverse applications and easy mining...
Anti-Inflammatory Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Anti-inflammatory therapeutics are mostly used to reduce inflammation. These drugs are types of analgesics that are used for reducing pain.Primarily, these therapeutics are used in disease conditions such as respiratory diseases, arthritis, inflammatory bowel diseases and multiple sclerosis. Anti-inflammatory therapeutics alleviate pain by counteracting the enzyme cyclooxygenase enzyme. These enzymes synthesize prostaglandins which is responsible for inflammation. These therapeutics reduce or prevent the secretion of prostaglandins and ultimately lower the severity of inflammation....

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Order cancellations not a sign of market slump: Airbus
Jul 31, 2014  
Leading aircraft manufacturer Airbus on Wednesday said that the recent wave of order cancellations for its commercial jetliners do not mean that the market has declined. The market is still strong and single-aisle jets deals are likely to return later. A total of 225 Airbus cancellations were reported since the beginning of this year. Of these, Dubai’s Emirates Airlines alone...
Leading Australian Universities Want to Hike Fees, Enroll Fewer Students
Jul 31, 2014  
Australia’s prestigious group of top eight universities, also known as the Group of Eight (Go8), has indicated plans of increasing tuition fees while reducing the number of students they enroll, a reform-backer has predicted. These decisions could be made if the universities are deregulated .  Arguing for this decision, the chairman of Go8, and vice chancellor of the ANU, Ian...
Bristol-Myers Squibb Posts USD 3.9 billion Revenues in 2014 Second Quarter
Jul 30, 2014  
Leading bio-pharmaceutical company Bristol-Myers Squibb has registered revenues of USD 3.9 billion in the 2014 second quarter. This marks a 4% decrease from the same period in 2013. The global revenues of the company (excluding the divested Diabetes Alliance), saw a 7% increase. In this quarter, the company’s results were underlined by steady global sales of nearly each of its...
Novartiss Simbrinza gets approval from the EU
Jul 30, 2014  
Glaucoma patients in Europe can easily obtain Novartis’ Simbrinza eye drops which are a combination of brimonidine tartrate and brinzolamide and it is without a beta-blocker. This eye drop has got the approval of the European Commission. Unlike the inefficient treatment provided by monotherapy, this eye drop aims at treating intraocular pressure or IOP in adults with ocular hypertension...
Second Treaty Between Zealand And Boehringer Ingelheim
Jul 30, 2014  
Denmark based Pharma group Zealand Pharma and Germany’s Boehringer Ingelheim have signed an accord to formulate new medicines for advanced and effective treatment of cardio-metabolic maladies. The collaboration between these two Pharma groups involves a new therapeutic peptide project from the list of preclinical programs of Zealand Pharma.  Both these companies are aiming...